**Name of journal: World Journal of Gastoenterology**

**ESPS Manuscript NO: 4756**

**Column: REVIEW**

**Sleep, immunity and inflammation in gastrointestinal disorders**

Ali T *et al.* Sleep and gastrointestinal disorders

Tauseef Ali, James Choe, Ahmed Awab, Theodore L Wagener, William C Orr

**Tauseef Ali,** Physicians Inflammatory Bowel Disease Center, University of Oklahoma, Oklahoma City, OK 73104, United States

**James Choe, William C Orr,** Department of Medicine, University of Oklahoma Health Science Center, Oklahoma City, OK 73104, United States

**Ahmed Awab,** Department of Medicine, Section of Pulmonary and Critical Care, Oklahoma City, OK 73104, United States

**Theodore L Wagener,** Department of Pediatrics, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, United States

**William C Orr,** Lynn Health Science Institute, Oklahoma City, OK 73112 United States

**Author contributions:** The idea was proposed by Ali T, Ali T and Choe J drafted the initial manuscript. Awab A, Wagener TL and Orr WC reviewed and edited the draft. All authors approved the final manuscript before submission.

**Correspondence to: Tauseef Ali, MD,** Physicians Inflammatory Bowel Disease Center, University of Oklahoma, 920 SL Young Blvd. WP 1345. Oklahoma City, OK 73104, United States. Tauseef-ali@ouhsc.edu

**Telephone:** +1-405-2715428 **Fax:** +1-405-2715803

**Received:** July 21, 2013 **Revised:** September 11, 2013

**Accepted:** September 29, 2013

**Published online:**

**Abstract**

Sleep disorders have become a global issue, and discovering their causes and consequences are the focus of many research endeavors. An estimated 70 million Americans suffer from some form of sleep disorder. Certain sleep disorders have been shown to cause neurocognitive impairment such as decreased cognitive ability, slower response times, and performance detriments. Recent research suggests that individuals with sleep abnormalities are also at greater risk of serious adverse health, economic consequences, and most importantly increased all-cause mortality. Several research studies support the associations among sleep, immune function and inflammation. Here, we review the current research linking sleep, immune function, and gastrointestinal diseases and discuss the interdependent relationship between sleep and these gastrointestinal disorders. Different physiologic processes including immune system and inflammatory cytokines help regulate the sleep. The inflammatory cytokines such as [tumor](app:ds:tumor) [necrosis](app:ds:necrosis) [factor](app:ds:factor), interleukin-1 (IL-1), and IL-6 have been shown to be a significant contributor of sleep disturbances. On the other hand, sleep disturbances such as sleep deprivation have been shown to up regulate these inflammatory cytokines. Alterations in these cytokine levels have been demonstrated in certain gastrointestinal diseases such as inflammatory bowel disease, gastro-esophageal reflux, liver disorders and colorectal cancer. In turn, abnormal sleep brought on by these diseases is shown to contribute to the severity of these same gastrointestinal diseases. Knowledge of these relationships will allow gastroenterologists a great opportunity to enhance the care of their patients.

© 2013 Baishideng. All rights reserved.

**Key words:** Sleep; immune function; immunity; irritable bowel syndrome; inflammatory bowel disease; Gastro-esophageal reflux disease; liver disorders; colon cancer; circadian rhythm

Ali T, Choe J, Awab A, Wagener TL, Orr WC. Sleep, immunity and inflammation in gastrointestinal disorders. *World J Gastroenterol* 2013;

**Available from:** URL: http://www.wjgnet.com/1007-9327/

**DOI:** http://dx.doi.org/10.3748/wjg.

**INTRODUCTION**

Research into sleep and its associated health abnormalities has had a relatively recent surge, and sleep quality has been shown in many investigations to be an important, if not essential element of good health[[1-3](#_ENREF_1" \o "Reid, 2006 #95)]. Sleep disorders can be primary, secondary or behavioral. Primary disorders are related to neurologic defects like narcolepsy and restless leg syndrome, breathing problems like obstructive sleep apnea and central sleep apnea, or circadian rhythm abnormalities like jet lag and delayed sleep phase syndrome. Secondary sleep disorders are secondary to primary diseases such as depression, chronic illness etc. Behavioral sleep problems such as insomnia or insufficient sleep are caused or perpetuated by poor sleep hygiene.

Sleep disorders have become a global issue. Sleep abnormalities occur in 17%-22% Japanese[[4](#_ENREF_4),[5](#_ENREF_5)], while sleep disorders are estimated to range from 7% to 50%in people living in Portugal and Finland [[6-8](#_ENREF_6)]. In the United States, more than 70 million people suffer from a sleep disorder, and modern lifestyles have led to Americans sleeping approximately 2 h less per night than 100 years ago[[4](#_ENREF_4),[7](#_ENREF_7),[9](#_ENREF_9)]. Abnormalities in the sleep cycle are linked with neurocognitive consequences ranging from performance decrements, slower response times, and decreased cognitive ability[[10](#_ENREF_10)].

Receiving fewer hours of sleep may also impact metabolism in a manner that contributes to obesity[[10](#_ENREF_10)]. A strong association has been found between disruption in sleep and gastrointestinal disease. We will review the interdependent relationship of sleep dysfunction and gastrointestinal issues including inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), gastro-esophageal reflux disease (GERD), liver disorders and colon cancer. Sleep abnormalities have been shown to worsen symptoms of IBS, IBD, and GERD which, in turn, can worsen sleep abnormalities. Sleep disorders and circadian dysfunction have also been shown to increase the risk of colon cancer.

**Human Sleep**

Sleep is classified based on polysomnographic data into two main categories known as rapid eye movement (REM) sleep and non-REM (NREM) sleep. NREM sleep is further divided into three stages based on increasing depths of sleep and increasing arousal thresholds. These sleep stages cycle through REM and NREM approximately every 90 min[[11](#_ENREF_11)]. More time is spent in slow-wave delta sleep each cycle during the first half of the night, with increasing time in REM sleep in the later portions of the night. Humans spend around 25% of total sleep time in REM sleep[[12](#_ENREF_12)]. The exact biological purpose of sleep is unknown. However, slow-wave sleep is thought to be restorative, restful sleep, and REM sleep is associated with dream recall and memory consolidation[[13](#_ENREF_13)]. Although the ideal quantity of sleep is different among individuals, most studies recommend seven to eight hours a night for adults as an optimal amount of sleep[[14](#_ENREF_14)]. Alterations in normal sleep patterns are thought to be a significant contributor to a vast array of illness including depression, metabolic syndrome, inflammation, gastrointestinal diseases, and also cancer[[15](#_ENREF_15),[16](#_ENREF_16)].

**Regulation of Sleep**

Sleep regulation is often described by a two process model[[17](#_ENREF_17)]. Process S, or the sleep homeostatic drive, linearly increases the longer an individual stays awake[[18](#_ENREF_18)]. Process C, or the circadian alerting drive, oscillates with body temperature on an approximate 24-h cycle [[15](#_ENREF_15),[18](#_ENREF_18)]. During the later hours of the day, Process C enters its decline in the circadian pattern, and Process S has accumulated approximately 16 h of continuous wakefulness. The combination of declining alertness and a sufficient amount of prior wakefulness facilitates the onset of sleep[[18](#_ENREF_18)]. Biological clocks have evolved based on a 24-h cycle that allow organisms to anticipate and physiologically adjust to daily environmental changes and this circadian system provides a temporal organization of waking and sleep[[15](#_ENREF_15),[19](#_ENREF_19)]. The circadian clock is entrained or synchronized to the specific day-night cycle (phase) of the environment through signals such as light, meals, and social interaction. These affect neuro hormonal pathways which influence the circadian clock. Light is the most important factor affecting the circadian rhythm. Light travels from the retina *via* the retinohypothalamic pathway to the suprachiasmatic nucleus (SCN), and then *via* a multi-synaptic pathway to the pineal gland where it suppresses melatonin production. Melatonin is a neurohormone that serves to synchronize circadian rhythms both with the environment and the human body as melatonin receptors are found in nearly all human tissue. Furthermore, the 24-h circadian rhythm is governed by a main circadian clock and a system of peripheral clocks located in multiple tissues including the pancreas, liver, and adipose tissue[[20](#_ENREF_20)]. The SCN also serves as a “standard time” which synchronizes peripheral tissue clocks[[21](#_ENREF_21)]. A series of “clock genes” help regulate the timing through both positive and negative feedback loops. CLOCK and BMAL-1 (Brain and Muscle Arnt-like protein) form heterodimers that accumulate throughout the day. These heterodimers then bind to the promoter regions of the genes Period (PER) and Cryptochrome (CRY) to activate their transcription. PER and CRY proteins then accumulate and form heterodimers that inhibit transcription of CLOCK and BMAL-1 proteins[[22](#_ENREF_22)]. Point mutations in these clock genes have been linked to altered circadian function and sleep abnormalities in mammals including familiar advanced sleep phase syndrome (FASPS) and delayed sleep phase syndrome (DSPS)[[23-25](#_ENREF_23)].

Research has also focused on determining whether similar feedback-loop clock genes are present within the gastrointestinal tract. *PER2* expression has been identified in the myenteric plexus and affects the rhythmic releases of acetylcholine and nitric oxide, ultimately regulating peristalsis[[26](#_ENREF_26),[27](#_ENREF_27)]. Hypotheses on circadian rhythms affecting nutrient transport in the small intestine, gastric acid secretion, gut motility, and production of digestive enzymes have also been proposed[[27](#_ENREF_27)].

**Immune Activation and Cytokine Effects on Sleep**

Many immune and endocrine pathways exhibit a diurnal profile including cortisol and growth hormone. The onset of sleep corresponds with an increase in the serum levels of some cytokines, peaking at 2.5 h after sleep onset[[28](#_ENREF_28)]. This surge of cytokines and their pro-inflammatory effects are suggested to be linked with nocturnal exacerbations of diseases like asthma and rheumatoid arthritis[[11](#_ENREF_11)]. Increasing evidence supports a reciprocal relationship between sleep and the immune system. An activated immune system alters sleep and sleep abnormalities affect immune function[[29](#_ENREF_29),[30](#_ENREF_30)]. Studies have also shown that an immune response elicits a pro-inflammatory cytokine response that helps to modulate sleep[[22](#_ENREF_22)]. This was first illustrated in the 1970s[[31](#_ENREF_31)] after the identification of a sleep-inducing muramyl peptide known as factor S was found to have both immune and sleep regulatory properties[[18](#_ENREF_18),[32](#_ENREF_32)]. Although the diverse range of cytokines released in early inflammation limits our ability to isolate individual contributions[[33](#_ENREF_33)], [tumor](app:ds:tumor) [necrosis](app:ds:necrosis) [factor](app:ds:factor) (TNF)-a, interleukin-1 (IL-1), and IL-6 have shown the strongest potential[[30](#_ENREF_30)]. However, numerous other cytokines with at least partial sleep regulatory properties have been identified. In animal models, IL-1 and TNF-a elevations have correlated with increased time in NREM sleep. Furthermore, an inhibitory effect on both spontaneous sleep and sleep rebound (increased REM sleep after sleep deprivation) was produced when IL-1 was inhibited by anti-IL-1 specific antibodies[[34](#_ENREF_34)]. In addition, high serum levels of TNF-a has been linked to sleepiness in patients with obstructive sleep apnea and rheumatoid arthritis[[35](#_ENREF_35),[36](#_ENREF_36)]. IL-6 also plays a role in sleep modulation. Sleep deprivation can increase IL-6 levels leading to daytime fatigue[[37](#_ENREF_37)]. In a human study, subjects received an injection of IL-6 that simulated the levels found in infection, and they experienced marked subjective fatigue, inhibition of REM sleep, and elevated CRP in 6.5 h[[33](#_ENREF_33)]. The inhibition of REM and the promotion of NREM sleep appear to play key roles in the immune response. IL-1, IL-6 and TNF-a are at high levels at time of infection and correlated with increased duration of NREM, changes in core body temperatures, more shivering, and an overall greater capacity to fight off illness[[32](#_ENREF_32)]. This was confirmed in several studies evaluating the effect of infection with HIV on sleep. In early stages of HIV infection, polysomnographic data showed larger percentage of time spent in NREM than in REM and prolonged REM sleep latency[[18](#_ENREF_18),[38](#_ENREF_38)]. Serotonin also is an integral component to IL-1 activity. Depletion of serotonin or inhibition of the serotonin receptor led to a reduction in the IL-1-induced increase in the amount of NREM sleep[[39](#_ENREF_39),[40](#_ENREF_40)]. Thus, there appears to be an interaction of IL-1 and its ability to modulate sleep based on baseline levels of serotonin. Infection caused by viral, bacterial, fungal or even parasites was evidenced to increase the amount of time spent in NREMS and decrease the amount of time spent in REMS[[41](#_ENREF_41)] based on severity of infection[[12](#_ENREF_12)].

**Sleep Effects on the Immune Response**

Both human and animal studies have shown that sleep has an overall protective role and that sleep deprivation is associated with an increased susceptibility to infection[[18](#_ENREF_18),[22](#_ENREF_22)]. A study on infected rabbits showed that animals who had longer periods of sleep had less morbidity and mortality[[43](#_ENREF_43)]. In humans, long-term sleep deprivation was shown to increase risk of septicemia[[44](#_ENREF_44)]. Furthermore, decreased sleep has been linked to impaired antibody response to hepatitis A vaccine[[29](#_ENREF_29)], influenza[[45](#_ENREF_45)], and increased risk of getting a URI[[46](#_ENREF_46)]. The timing of sleep is also important because most immune cells have their highest response to immune challenges during the night[[12](#_ENREF_12),[18](#_ENREF_18)] and their lowest response in the morning[[45](#_ENREF_45)]. This antibody impairment is very similar to the decrease in the immune response seen with human aging as both have a lowered T-cell response to antigens and impaired response to vaccinations[[47](#_ENREF_47)].

**Gastroesophageal Reflux Disease and Sleep**

It is well established that gastroesophageal reflux and its most common symptoms, heartburn and regurgitation, is among the most frequently dealt with conditions encountered by gastroenterologists[[48](#_ENREF_48)].

Approximately, 10%-20% of the people in the United States have GERD[[49](#_ENREF_49)]. One study found that approximately 74% of patients with GERD had nocturnal symptoms[[50](#_ENREF_50)]. A Gallup survey revealed that approximately 63% of the people with nocturnal GERD felt it impaired their ability to sleep and 40% felt it impaired their ability the following day[[51](#_ENREF_51)].Several factors likely contribute to nocturnal GERD. Numerous studies now have documented that reflux during sleep presents physiologic issues not encountered during the waking state. For example there is a notable prolongation of acid clearance due to the suppression of swallowing and salivation during sleep. This results in enhanced back diffusion of hydrogen ions and subsequent mucosal damage. These issues are discussed in detail in a review by Orr in which he presents an argument for considering nighttime reflux and its clinical manifestations as a distinct clinical entity[[52](#_ENREF_52)]. However, sleep and GERD have been shown to have a more interdependent relationship. A study by Dickman and colleagues noted that poor quality of sleep led to exacerbations of reflux the following day[[53](#_ENREF_53)]. They also found that longer durations of reflux events correlated with reduced sleep quality[[53](#_ENREF_53)]. This was supported by the Gallup survey, a higher frequency of reflux was associated with higher frequency of sleep difficulties[[51](#_ENREF_51)]. A likely contributing factor is the hyperalgesia due to sleep disturbances[[54](#_ENREF_54),[55](#_ENREF_55)]. This was first reported by Onen *et al*[[54](#_ENREF_54)] who found that sleep deprivation led to a somatic hyperalgesia. This hyperalgesia was evidenced after loss of REM sleep or cumulative 2 d loss of non-REM sleep[[54](#_ENREF_54)]. Recently, Schey *et al*[[55](#_ENREF_55" \o "Schey, 2007 #36)] have documented a visceral hyperalgesia and increased sensitivity to reflux in GERD patients with documented poor sleep prior to undergoing an acid perfusion test. Further research in this area is needed, but current studies indicate that discussion and treatment of sleep abnormalities in patients with GERD may lead to improved management.

**Peptic Ulcer Disease**

Patients with sleep apnea sustain cessation of breath during sleep, leading to intermittent hypoxia, systemic inflammation, and sympathetic activation. These insults are not only be a threat to cardiovascular system but can also contribute to damage to the gastrointestinal mucosa and hence initiation or progression of peptic ulcers[[56](#_ENREF_56)]. In a very large study of nearly 35000 patients from Taiwan, patients with sleep apnea experienced 2.4 fold higher risk for peptic ulcer bleeding[[56](#_ENREF_56)]. This may warrant surveying for sleep apnea as a potential predisposing factor in patients with peptic ulcer bleeding and without any apparent risk factors.

**Inflammatory Bowel Disease and Sleep**

Inflammatory bowel disease (IBD) is characterized by a chronic immune mediated inflammation of the gastrointestinal tract. It is estimated that approximately 400/100000 Americans suffer from IBD[[57](#_ENREF_57" \o "Kappelman, 2007 #38)]. The relationship between sleep and IBD has been a topic of more recent consideration. Ranjbaran and colleagues used the Pittsburgh Sleep Quality Index (PSQI) to show a relationship with sleep abnormalities and the quality of life in patients with IBD. They noted several sleep-related issues: more sleep latency, less day time energy, and increased sleeping pill use[[58](#_ENREF_58)].

Abnormal sleeping habits may also play a role on disease severity. One study noted both worsened severity of UC and higher mortality in phase-shifted mice than in unaltered circadian–phase mice[[59](#_ENREF_59" \o "Preuss, 2008 #40)]. They noted that chronic circadian phase shifts led to worsening mucosal inflammation and colitis likely secondary to altered inflammatory cascade regulation[[59](#_ENREF_59" \o "Preuss, 2008 #40)]. Another study found that occupations that have artificial working conditions (such as light) and irregular hours had higher odds ratio (1.6–1.7) for development for IBD[[60](#_ENREF_60),[61](#_ENREF_61)].

Patients with CD and sleep loss may also have a greater risk for disease relapse. These patients had twice the risk of active disease in 6 mo than patients who did not have sleep abnormalities[[62](#_ENREF_62)]. In fact, Tang and colleagues performed a study examining sleep deprivation on mice with colitis and noted both acute and chronic sleep deprivation led to worsening colitis likely secondary to heightened sensitivity to pro-inflammatory cytokines such as IL-6 and TNF-a[[9](#_ENREF_9),[30](#_ENREF_30),[61](#_ENREF_61),[63](#_ENREF_63)].A large survey study looking at sleep disturbances in over 3100 participants found that CD patients in clinical remission and subjective sleep disturbances had a 2-fold increased risk of active disease at 6 mo. They discovered approximately 75% of patients with active disease have subjective sleep complaints compared to 48% inactive disease[[62](#_ENREF_62)].

Recently, we performed a prospective observational cohort study looking at the sleep disturbances of IBD patients. We discovered that 100% of patients with active disease had poor sleep while only 72% of patients with clinically inactive disease had poor sleep. The difference between sleep disturbances became even higher when histology was used to define the disease activity. We found 100% of those in histologically active group had poor sleep while only 54% in the histologically inactive group had poor sleep (OR, 6.0, 95%CI: 2.9-12.5, *P* < 0.0001). An abnormal PSQI had a positive predictive value for histologic inflammatory activity of 83%[[64](#_ENREF_64)]. These patients were prospectively followed for 6 mo, and the relapse rate in clinically inactive patients with poor sleep was found to be 67%. No patients with normal sleep patterns relapsed (RR = 3, 95%CI 1.5 to 6.1, *P* = 0.03). We detected a significant correlation between the baseline PSQI and disease activity at the 6-month follow up (CD: *r* = 0.56, *P* = 0.0046; UC: *r* = 0.54, *P* = 0.024)[[65](#_ENREF_65)]. Although the study was limited by the small number of patients, the results are intriguing and hold very important therapeutic implication in the management of immune-mediated inflammatory diseases.

Melatonin has recently been investigated as a possible method of improving outcomes for patients with UC Data from several animal models indicate that melatonin administration increased serum levels of IL-10 (an anti-inflammatory cytokine) and decreased serum levels of pro-inflammatory cytokines such as IL-6 and TNF-a[[66-69](#_ENREF_66)]. Patients with UC had abnormally high levels of pro-inflammatory cytokines, and melatonin may play a role in reducing the severity of UC by reducing these specific cytokines[[69-73](#_ENREF_69" \o "Terry, 2009 #50)].

**Irritable Bowel Syndrome and Sleep**

IBS is a chronic gastrointestinal syndrome that is associated with abdominal pain and distorted bowel behavior. IBS is commonly diagnosed and there is an estimated 10%-15% of the North American population suffering from this syndrome[[74](#_ENREF_74)]. IBS appears to have a significant association with anxiety, stress, and overall environment. Interestingly, sleep dysfunction also has similar associations. The study conducted by Kim *et al*[[75](#_ENREF_75)] examined IBS occurrence among irregular-shift workers and traditional day-shift workers. They found that the prevalence of IBS in irregular-shift workers was significantly higher (32.7%) than in the day-shift workers (16.7%). They also found that many of the individuals that worked irregular shifts experienced less sleep quality, higher rates of daytime sleepiness, and higher levels of stress[[75](#_ENREF_75)]. Chen *et al*[[76](#_ENREF_76)] compared sleep patterns and rectal sensitivity using anorectal manometry among patients with IBS and healthy subjects. They noted that IBS patients with lower amounts of quality sleep were prone to lower thresholds for rectal sensitivity and altered anal sphincter function. This rectal hyperalgesia in patients with sleep abnormalities and IBS is consistent with the visceral hyperalgesia noted in patients with sleep abnormalities and GERD[[55](#_ENREF_55" \o "Schey, 2007 #36)].

**COLON CANCER AND SLEEP**

Colorectal cancer is the second most commonly diagnosed cancer in the world in women and the third most common in men[[77](#_ENREF_77)]. Surgery is often the primary method of intervention while adjuvant chemotherapy and radiation therapy are often employed to improve survival or quality of life[[78-80](#_ENREF_78" \o "Berger, 2010 #59)]. Several surveys noted that fatigue was one of the highest concerns for people with cancer[[78](#_ENREF_78),[81](#_ENREF_81),[82](#_ENREF_82)].

Animal studies indicate that both circadian disruption by nocturnal light exposure or sleep deprivation accelerated tumor formation[[83-85](#_ENREF_83" \o "Guess, 2009 #64)]. A recent study by Thompson and colleagues evaluated sleep and colon cancer and noted that shorter duration of sleep (< 6 h) led to an almost 50% increase in the risk for colorectal adenomas[[86](#_ENREF_86)]. Shift work, abnormal clock gene expression, and other causes of disruption of circadian rhythms are emerging as cancer risk factors[[83](#_ENREF_83),[87](#_ENREF_87)]. A study by Schernhammer *et al*[[88](#_ENREF_88" \o "Schernhammer, 2003 #69)] found an increased risk for colon cancer in women who worked night shifts. Several theories have been proposed to explain the relationship between sleep and colon cancer. Increased obesity is a known risk factor for cancer[[89](#_ENREF_89)]. Sleep disorders are also known to alter metabolism and contribute to obesity[[10](#_ENREF_10)]. Sleep disturbance may play an indirect role in increasing the risk for cancer by increasing adiposity[[90](#_ENREF_90)]. Another theory suggests melatonin and its anti-carcinogenic properties are a key factor. Nocturnal light exposure suppresses melatonin production, and the lack of melatonin and its anti-proliferative effects may contribute to intestinal cancer formation[[88](#_ENREF_88),[91](#_ENREF_91)]. Open discussion, evaluation, and treatment of lower-than-normal duration of sleep may be an under-appreciated method of colorectal cancer risk modification.

**Sleep Dysfunction and the Liver**

Sleep disturbances are seen in numerous types of liver diseases. One study found 47.7% of cirrhotic patients had unsatisfactory sleep when compared to 4.5% seen in controls[[92](#_ENREF_92)]. Elevated levels of ammonia seen in hepatic encephalopathy is also evidenced to induce sleep wake cycle reversal and progressive EEG changes with triphasic wave changes in Stage I hepatic encephalopathy and eventually delta waves and comatose state in Stage IV[[93](#_ENREF_93)]. Another study found that women with primary biliary cirrhosis slept nearly twice as much during the day when compared to controls[[94](#_ENREF_94)]. Although the exact mechanism behind this is known, it is thought that elevated IL-6 plays a role[[95](#_ENREF_95)]. Patients with hepatitis C also are at higher risk for sleep abnormalities with 60%-65% reporting abnormal sleep complaints[[96](#_ENREF_96)]. In addition, patients undergoing treatment with interferon-a are also at increased risk for sleep abnormalities as 22%-24% of patients experience sleep disturbance as a side effect[[97](#_ENREF_97)].

Summa *et al*[[98](#_ENREF_98)] study on mice found that circadian disorganization *via* ClockΔ19/Δ19mutation led to elevated liver/body weight ratios and advanced alcohol induced steatohepatitis. The etiology behind this connection is thought to rely on abnormal intestinal epithelial permeability. Ideally, the intestinal epithelial barrier serves to protect the body from unwanted luminal contents while also allowing a fraction of permeability to allow immune surveillance and regulation[[99](#_ENREF_99)]. Summa *et al*[[98](#_ENREF_98)] followed the absorption of sugars in the gastrointestinal tract in phase shifted mice and found increased permeability in the colon when compared to control. This evidence indicates that circadian dysfunction may be a separate risk factor for alcohol induced liver damage[[98](#_ENREF_98)].

Patients with sleep apnea sustain cessation of breath during sleep, leading to intermittent hypoxia, systemic inflammation, and sympathetic activation. These insults may contribute to initiation or progression of peptic ulcers[[56](#_ENREF_56)]. In a very large study of nearly 35000 patients from Taiwan, patients with sleep apnea experienced 2.4 fold higher risk for peptic ulcer bleeding[[56](#_ENREF_56)].

**Treatment Implications**

As the complexities regarding the association between sleep and gastrointestinal disorders continue to become better understood, it begs the question as to how the medical and psychiatric community should address comorbid sleep and gastrointestinal disorders. Though current clinical trials have not directly addressed this population, several small preliminary trials have investigated the efficacy of cognitive behavioral therapy for insomnia (CBT-I) in patients with comorbid chronic pain[[100-104](#_ENREF_100" \o "Rybarczyk, 2005 #128)]. Collectively, these studies suggest that insomnia can be effectively treated among patients with chronic pain and that improvement in sleep confers some clinical improvement in pain. Therefore, given the state of the current science, it seems prudent that medical providers would recommend the evaluation and treatment of sleep disorders in patients with gastrointestinal disorders. Treating both disorders in parallel may not only result in a better outcome for the patient, but also allow the medical provider to use less invasive and expensive means to improve the patient’s overall quality of life.

**CONCLUSION**

Sleep abnormalities are a global issue and its effects on well-known pathologies is both an interesting and relevant field of research. Sleep abnormalities contribute to many gastrointestinal diseases and conversely, gastrointestinal diseases often lead to sleep abnormalities. This interdependent relationship represents a novel approach to treating GERD, IBS, IBD, liver disorders and colon cancer. The evaluation, discussion, and treatment of sleep abnormalities may play a key role in further preventing and improving many gastrointestinal disorders.

**REFERENCES**

1 **Reid KJ**, Martinovich Z, Finkel S, Statsinger J, Golden R, Harter K, Zee PC. Sleep: a marker of physical and mental health in the elderly. *Am J Geriatr Psychiatry* 2006; **14**: 860-866 [PMID: 17001025 DOI: 10.1097/01.JGP.0000206164.56404.ba]

2 **Zee PC**, Turek FW. Sleep and health: Everywhere and in both directions. *Arch Intern Med* 2006; **166**: 1686-1688 [PMID: 16983044 DOI: 10.1001/archinte.166.16.1686]

3 **Luyster FS**, Strollo PJ, Zee PC, Walsh JK. Sleep: a health imperative. *Sleep* 2012; **35**: 727-734 [PMID: 22654183 DOI: 10.5665/sleep.1846]

4 **Johnson DA**. Gastroesophageal reflux disease and sleep disorders: a wake-up call for physicians and their patients. *Rev Gastroenterol Disord* 2005; **5** Suppl 2: S3-11 [PMID: 16369222]

5 **Kim K**, Uchiyama M, Okawa M, Liu X, Ogihara R. An epidemiological study of insomnia among the Japanese general population. *Sleep* 2000; **23**: 41-47 [PMID: 10678464]

6 **Fetveit A**, Straand J, Bjorvatn B. Sleep disturbances in an arctic population: the Tromsø Study. *BMC Health Serv Res* 2008; **8**: 117 [PMID: 18510767 DOI: 10.1186/1472-6963-8-117]

7 **Maneerattanaporn M**, Chey WD. Sleep disorders and gastrointestinal symptoms: chicken, egg or vicious cycle? *Neurogastroenterol Motil* 2009; **21**: 97-99 [PMID: 19215586 DOI: 10.1111/j.1365-2982.2008.01254.x]

8 **Ohayon MM**, Paiva T. Global sleep dissatisfaction for the assessment of insomnia severity in the general population of Portugal. *Sleep Med* 2005; **6**: 435-441 [PMID: 16085459 DOI: 10.1016/j.sleep.2005.03.006]

9 **Orr WC**. Sleep and gastrointestinal disease: a new horizon in sleep medicine. *Sleep Med* 2009; **10**: 595-596 [PMID: 19403334 DOI: 10.1016/j.sleep.2009.03.001]

10 **Balkin TJ**, Rupp T, Picchioni D, Wesensten NJ. Sleep loss and sleepiness: current issues. *Chest* 2008; **134**: 653-660 [PMID: 18779203 DOI: 10.1378/chest.08-1064]

11 **Palma BD**, Tiba PA, Machado RB, Tufik S, Suchecki D. [Immune outcomes of sleep disorders: the hypothalamic-pituitary-adrenal axis as a modulatory factor]. *Rev Bras Psiquiatr* 2007; **29** Suppl 1: S33-S38 [PMID: 17546346]

12 **Shearer WT**, Reuben JM, Mullington JM, Price NJ, Lee BN, Smith EO, Szuba MP, Van Dongen HP, Dinges DF. Soluble TNF-alpha receptor 1 and IL-6 plasma levels in humans subjected to the sleep deprivation model of spaceflight. *J Allergy Clin Immunol* 2001; **107**: 165-170 [PMID: 11150007 DOI: 10.1067/mai.2001.112270]

13 **Stickgold R**. Sleep-dependent memory consolidation. *Nature* 2005; **437**: 1272-1278 [PMID: 16251952 DOI: 10.1038/nature04286]

14 **Balachandran D**. Sleep and the immune system: implications for health and mortality. *Sleep and Safety* 2011; 52-59

15 **Czeisler CA**, Gooley JJ. Sleep and circadian rhythms in humans. *Cold Spring Harb Symp Quant Biol* 2007; **72**: 579-597 [PMID: 18419318 DOI: 10.1101/sqb.2007.72.064]

16 **Bechtold DA**, Gibbs JE, Loudon AS. Circadian dysfunction in disease. *Trends Pharmacol Sci* 2010; **31**: 191-198 [PMID: 20171747 DOI: 10.1016/j.tips.2010.01.002]

17 **Borbély AA**. Refining sleep homeostasis in the two-process model. *J Sleep Res* 2009; **18**: 1-2 [PMID: 19250170 DOI: 10.1111/j.1365-2869.2009.00750.x]

18 **Gamaldo CE,** Shaikh AK, McArthur JC. The Sleep-Immunity Relationship. Neurologic clinics. 2012; **30:** 1313-43 [PDIM: 23099104]

19 **Panda S**, Hogenesch JB, Kay SA. Circadian rhythms from flies to human. *Nature* 2002; **417**: 329-335 [PMID: 12015613 DOI: 10.1038/417329a]

20 **Delezie J**, Challet E. Interactions between metabolism and circadian clocks: reciprocal disturbances. *Ann N Y Acad Sci* 2011; **1243**: 30-46 [PMID: 22211891 DOI: 10.1111/j.1749-6632.2011.06246.x]

21 **Bass J**, Takahashi JS. Circadian integration of metabolism and energetics. *Science* 2010; **330**: 1349-1354 [PMID: 21127246 DOI: 10.1126/science.1195027]

22 **Bollinger T**, Bollinger A, Oster H, Solbach W. Sleep, immunity, and circadian clocks: a mechanistic model. *Gerontology* 2010; **56**: 574-580 [PMID: 20130392 DOI: 10.1159/000281827]

23 **Jones CR**, Campbell SS, Zone SE, Cooper F, DeSano A, Murphy PJ, Jones B, Czajkowski L, Ptácek LJ. Familial advanced sleep-phase syndrome: A short-period circadian rhythm variant in humans. *Nat Med* 1999; **5**: 1062-1065 [PMID: 10470086 DOI: 10.1038/12502]

24 **Kyriacou CP**, Hastings MH. Circadian clocks: genes, sleep, and cognition. *Trends Cogn Sci* 2010; **14**: 259-267 [PMID: 20418150 DOI: 10.1016/j.tics.2010.03.007]

25 **Toh KL**, Jones CR, He Y, Eide EJ, Hinz WA, Virshup DM, Ptácek LJ, Fu YH. An hPer2 phosphorylation site mutation in familial advanced sleep phase syndrome. *Science* 2001; **291**: 1040-1043 [PMID: 11232563]

26 **Hoogerwerf WA**. Role of biological rhythms in gastrointestinal health and disease. *Rev Endocr Metab Disord* 2009; **10**: 293-300 [PMID: 19798581 DOI: 10.1007/s11154-009-9119-3]

27 **Konturek PC**, Brzozowski T, Konturek SJ. Gut clock: implication of circadian rhythms in the gastrointestinal tract. *J Physiol Pharmacol* 2011; **62**: 139-150 [PMID: 21673361]

28 **Haus E**, Smolensky MH. Biologic rhythms in the immune system. *Chronobiol Int* 1999; **16**: 581-622 [PMID: 10513884]

29 **Lange T**, Dimitrov S, Born J. Effects of sleep and circadian rhythm on the human immune system. *Ann N Y Acad Sci* 2010; **1193**: 48-59 [PMID: 20398008 DOI: 10.1111/j.1749-6632.2009.05300.x]

30 **Ranjbaran Z**, Keefer L, Stepanski E, Farhadi A, Keshavarzian A. The relevance of sleep abnormalities to chronic inflammatory conditions. *Inflamm Res* 2007; **56**: 51-57 [PMID: 17431741 DOI: 10.1007/s00011-006-6067-1]

31 **Majde JA**, Krueger JM. Links between the innate immune system and sleep. *J Allergy Clin Immunol* 2005; **116**: 1188-1198 [PMID: 16337444 DOI: 10.1016/j.jaci.2005.08.005]

32 **Imeri L**, Opp MR. How (and why) the immune system makes us sleep. *Nat Rev Neurosci* 2009; **10**: 199-210 [PMID: 19209176 DOI: 10.1038/nrn2576]

33 **Späth-Schwalbe E**, Hansen K, Schmidt F, Schrezenmeier H, Marshall L, Burger K, Fehm HL, Born J. Acute effects of recombinant human interleukin-6 on endocrine and central nervous sleep functions in healthy men. *J Clin Endocrinol Metab* 1998; **83**: 1573-1579 [PMID: 9589658]

34 **Opp MR**, Krueger JM. Anti-interleukin-1 beta reduces sleep and sleep rebound after sleep deprivation in rats. *Am J Physiol* 1994; **266**: R688-R695 [PMID: 8160860]

35 **Franklin CM**. Clinical experience with soluble TNF p75 receptor in rheumatoid arthritis. *Semin Arthritis Rheum* 1999; **29**: 172-181 [PMID: 10622681]

36 **Vgontzas AN**, Papanicolaou DA, Bixler EO, Kales A, Tyson K, Chrousos GP. Elevation of plasma cytokines in disorders of excessive daytime sleepiness: role of sleep disturbance and obesity. *J Clin Endocrinol Metab* 1997; **82**: 1313-1316 [PMID: 9141509]

37 **Vgontzas AN**, Papanicolaou DA, Bixler EO, Lotsikas A, Zachman K, Kales A, Prolo P, Wong ML, Licinio J, Gold PW, Hermida RC, Mastorakos G, Chrousos GP. Circadian interleukin-6 secretion and quantity and depth of sleep. *J Clin Endocrinol Metab* 1999; **84**: 2603-2607 [PMID: 10443646]

38 **Norman SE**, Chediak AD, Kiel M, Cohn MA. Sleep disturbances in HIV-infected homosexual men. *AIDS* 1990; **4**: 775-781 [PMID: 2261133]

39 **Opp MR.** Cytokines and sleep. Sleep medicine reviews. 2005; **9:** 355-64 [PMID: 16102986]

40 **Gemma C**, Imeri L, Opp MR. Serotonergic activation stimulates the pituitary-adrenal axis and alters interleukin-1 mRNA expression in rat brain. *Psychoneuroendocrinology* 2003; **28**: 875-884 [PMID: 12892655]

41 **Toth LA**. Microbial modulation of sleep. In: R L, editor. Handbook of behav state cntrl: cellu and molec mechs. Boca Raton (FL): CRC Press; 1999: pp 641-57

42 **Toth LA**, Tolley EA, Krueger JM. Sleep as a prognostic indicator during infectious disease in rabbits. *Proc Soc Exp Biol Med* 1993; **203**: 179-192 [PMID: 8502660]

43 **Everson CA**. Sustained sleep deprivation impairs host defense. *Am J Physiol* 1993; **265**: R1148-R1154 [PMID: 8238617]

44 **Spiegel K**, Sheridan JF, Van Cauter E. Effect of sleep deprivation on response to immunization. *JAMA* 2002; **288**: 1471-1472 [PMID: 12243633]

45 **Cohen FL**, Ferrans CE, Vizgirda V, Kunkle V, Cloninger L. Sleep in men and women infected with human immunodeficiency virus. *Holist Nurs Pract* 1996; **10**: 33-43 [PMID: 8717996]

46 **Perras BB,** Jan. Sleep associated endocrine and immune changes in the elderly. *Adv Cell Aging Gerontol* 2005; 16: 113-54 [DOI: 10.1016/S1566-3124(04)17005-3]

47 **DeVault KR**, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. *Am J Gastroenterol* 2005; **100**: 190-200 [PMID: 15654800 DOI: 10.1111/j.1572-0241.2005.41217.x]

48 **Dent J**, El-Serag HB, Wallander MA, Johansson S. Epidemiology of gastro-oesophageal reflux disease: a systematic review. *Gut* 2005; **54**: 710-717 [PMID: 15831922 DOI: 10.1136/gut.2004.051821]

49 **Farup C**, Kleinman L, Sloan S, Ganoczy D, Chee E, Lee C, Revicki D. The impact of nocturnal symptoms associated with gastroesophageal reflux disease on health-related quality of life. *Arch Intern Med* 2001; **161**: 45-52 [PMID: 11146697 DOI: [10.1001/archinte.161.1.45](http://dx.doi.org/10.1001/archinte.161.1.45)]

50 **Shaker R**, Castell DO, Schoenfeld PS, Spechler SJ. Nighttime heartburn is an under-appreciated clinical problem that impacts sleep and daytime function: the results of a Gallup survey conducted on behalf of the American Gastroenterological Association. *Am J Gastroenterol* 2003; **98**: 1487-1493 [PMID: 12873567 DOI: 10.1111/j.1572-0241.2003.07531.x]

51 **Orr WC**. Review article: sleep-related gastro-oesophageal reflux as a distinct clinical entity. *Aliment Pharmacol Ther* 2010; **31**: 47-56 [PMID: 19691671 DOI: 10.1111/j.1365-2036.2009.04124.x]

52 **Dickman R**, Green C, Fass SS, Quan SF, Dekel R, Risner-Adler S, Fass R. Relationships between sleep quality and pH monitoring findings in persons with gastroesophageal reflux disease. *J Clin Sleep Med* 2007; **3**: 505-513 [PMID: 17803014]

53 **Onen SH**, Alloui A, Gross A, Eschallier A, Dubray C. The effects of total sleep deprivation, selective sleep interruption and sleep recovery on pain tolerance thresholds in healthy subjects. *J Sleep Res* 2001; **10**: 35-42 [PMID: 11285053 DOI: [10.1046/j.1365-2869.2001.00240.x](http://dx.doi.org/10.1046/j.1365-2869.2001.00240.x)]

54 **Schey R**, Dickman R, Parthasarathy S, Quan SF, Wendel C, Merchant J, Powers J, Han B, van Handel D, Fass R. Sleep deprivation is hyperalgesic in patients with gastroesophageal reflux disease. *Gastroenterology* 2007; **133**: 1787-1795 [PMID: 18054551 DOI: 10.1053/j.gastro.2007.09.039]

55 **Huang KW,** Luo JC, Leu HB, Lin HC, Lee FY, Chan WL, et al. Chronic obstructive pulmonary disease: an independent risk factor for peptic ulcer bleeding: a nationwide population-based study. Aliment Pharmacol Ther. 2012; 35(7): 796-802 [pmid: 22348540 doi: 10.1111/j.365-2036.12.05028.x. Epub 2012 Feb 21]

56 **Kappelman MD**, Rifas-Shiman SL, Kleinman K, Ollendorf D, Bousvaros A, Grand RJ, Finkelstein JA. The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States. *Clin Gastroenterol Hepatol* 2007; **5**: 1424-1429 [PMID: 17904915 DOI: 10.1016/j.cgh.2007.07.012]

57 **Ranjbaran Z,** Keefer, L., Farhadi, A., Stepanski, E.,. Impact of sleep disturbances in inflammatory bowel disease. Journal of gastroenterology and hepatology. 2007; 22(11): 1748-53 [pmid: 17914945 DOI: [10.1111/j.1440-1746.2006.04820.x](http://dx.doi.org/10.1111/j.1440-1746.2006.04820.x)]

58 **Preuss F**, Tang Y, Laposky AD, Arble D, Keshavarzian A, Turek FW. Adverse effects of chronic circadian desynchronization in animals in a "challenging" environment. *Am J Physiol Regul Integr Comp Physiol* 2008; **295**: R2034-R2040 [PMID: 18843092 DOI: 10.1152/ajpregu.00118.2008]

59 **Sonnenberg A**. Occupational distribution of inflammatory bowel disease among German employees. *Gut* 1990; **31**: 1037-1040 [PMID: 2210450 DOI: [10.1136/gut.31.9.1037](http://dx.doi.org/10.1136/gut.31.9.1037)]

60 **Swanson GR**, Burgess HJ, Keshavarzian A. Sleep disturbances and inflammatory bowel disease: a potential trigger for disease flare? *Expert Rev Clin Immunol* 2011; **7**: 29-36 [PMID: 21162647 DOI: 10.1586/eci.10.83]

61 **Ananthakrishnan AN**, Long MD, Martin CF, Sandler RS, Kappelman MD. Sleep disturbance and risk of active disease in patients with Crohn's disease and ulcerative colitis. *Clin Gastroenterol Hepatol* 2013; **11**: 965-971 [PMID: 23376797 DOI: 10.1016/j.cgh.2013.01.021]

62 **Tang Y**, Preuss F, Turek FW, Jakate S, Keshavarzian A. Sleep deprivation worsens inflammation and delays recovery in a mouse model of colitis. *Sleep Med* 2009; **10**: 597-603 [PMID: 19403332 DOI: 10.1016/j.sleep.2008.12.009]

63 **Ali T,** Madhoun MF, Orr WC, Rubin DT. Assessment of the Relationship Between Quality of Sleep and Disease Activity in Inflammatory Bowel Disease Patients. *Inflamm Bowel Dis* 2013 [PMID: 23945186 DOI: 10.1097/MIB.0b013e3182a0ea54]

64 **Ali T,** Madhoun MF, Crosby A, Orr WC, Rubin DT. Poor Sleep Quality Predicts Disease Relapse in Patients With Inflammatory Bowel Disease. *Gastroenterology* 2013, **144** Supplement 1**:** S-12

65 **De Filippis D**, Iuvone T, Esposito G, Steardo L, Arnold GH, Paul AP, De Man Joris G, De Winter Benedicte Y. Melatonin reverses lipopolysaccharide-induced gastro-intestinal motility disturbances through the inhibition of oxidative stress. *J Pineal Res* 2008; **44**: 45-51 [PMID: 18078447 DOI: 10.1111/j.1600-079X.2007.00526.x]

66 **Carrillo-Vico A**, Guerrero JM, Lardone PJ, Reiter RJ. A review of the multiple actions of melatonin on the immune system. *Endocrine* 2005; **27**: 189-200 [PMID: 16217132 DOI: 10.1385/endo: 27: 2: 189]

67 **Johe PD**, Østerud B. The in vivo effect of melatonin on cellular activation processes in human blood during strenuous physical exercise. *J Pineal Res* 2005; **39**: 324-330 [PMID: 16150115 DOI: 10.1111/j.1600-079X.2005.00254.x]

68 **Terry PD**, Villinger F, Bubenik GA, Sitaraman SV. Melatonin and ulcerative colitis: evidence, biological mechanisms, and future research. *Inflamm Bowel Dis* 2009; **15**: 134-140 [PMID: 18626968 DOI: 10.1002/ibd.20527]

69 **Ishiguro Y**. Mucosal proinflammatory cytokine production correlates with endoscopic activity of ulcerative colitis. *J Gastroenterol* 1999; **34**: 66-74 [PMID: 10204613 DOI: [10.1007/s005350050218](http://dx.doi.org/10.1007/s005350050218)]

70 **Olsen T**, Goll R, Cui G, Husebekk A, Vonen B, Birketvedt GS, Florholmen J. Tissue levels of tumor necrosis factor-alpha correlates with grade of inflammation in untreated ulcerative colitis. *Scand J Gastroenterol* 2007; **42**: 1312-1320 [PMID: 17852866 DOI: 10.1080/00365520701409035]

71 **Umehara Y**, Kudo M, Nakaoka R, Kawasaki T, Shiomi M. Serum proinflammatory cytokines and adhesion molecules in ulcerative colitis. *Hepatogastroenterology* ; **53**: 879-882 [PMID: 17153445]

72 **Sands BE**, Kaplan GG. The role of TNFalpha in ulcerative colitis. *J Clin Pharmacol* 2007; **47**: 930-941 [PMID: 17567930 DOI: 10.1177/0091270007301623]

73 **Talley NJ**, Zinsmeister AR, Van Dyke C, Melton LJ. Epidemiology of colonic symptoms and the irritable bowel syndrome. *Gastroenterology* 1991; **101**: 927-934 [PMID: 1889716]

74 **Kim HI**, Jung SA, Choi JY, Kim SE, Jung HK, Shim KN, Yoo K. Impact of shiftwork on irritable bowel syndrome and functional dyspepsia. *J Korean Med Sci* 2013; **28**: 431-437 [PMID: 23487413 DOI: 10.3346/jkms.2013.28.3.431]

75 **Chen CL**, Liu TT, Yi CH, Orr WC. Evidence for altered anorectal function in irritable bowel syndrome patients with sleep disturbance. *Digestion* 2011; **84**: 247-251 [PMID: 21952561 DOI: 10.1159/000330847]

76 **Jemal A**, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. *CA Cancer J Clin*; **61**: 69-90 [PMID: 21296855 DOI: 10.3322/caac.20107]

77 **Berger AM**, Grem JL, Visovsky C, Marunda HA, Yurkovich JM. Fatigue and other variables during adjuvant chemotherapy for colon and rectal cancer. *Oncol Nurs Forum* 2010; **37**: E359-E369 [PMID: 21059569 DOI: 10.1188/10.onf.e359-e369]

78 **Cera SM**, Wexner SD. Minimally invasive treatment of colon cancer. *Cancer J* ; **11**: 26-35 [PMID: 15831221 DOI: [10.1097/00130404-200501000-00005](http://dx.doi.org/10.1097/00130404-200501000-00005)]

79 **Shelton BK**. Introduction to colorectal cancer. *Semin Oncol Nurs* 2002; **18**: 2-12 [PMID: 12053860 DOI: [10.1053/sonu.2002.33074](http://dx.doi.org/10.1053/sonu.2002.33074)]

80 **Ward WL**, Hahn EA, Mo F, Hernandez L, Tulsky DS, Cella D. Reliability and validity of the Functional Assessment of Cancer Therapy-Colorectal (FACT-C) quality of life instrument. *Qual Life Res* 1999; **8**: 181-195 [PMID: 10472150 DOI: [10.1023/A:1008821826499](http://dx.doi.org/10.1023/A:1008821826499)]

81 **Osoba D**, Hsu MA, Copley-Merriman C, Coombs J, Johnson FR, Hauber B, Manjunath R, Pyles A. Stated preferences of patients with cancer for health-related quality-of-life (HRQOL) domains during treatment. *Qual Life Res* 2006; **15**: 273-283 [PMID: 16468082 DOI: 10.1007/s11136-005-0580-5]

82 **Guess J**, Burch JB, Ogoussan K, Armstead CA, Zhang H, Wagner S, Hebert JR, Wood P, Youngstedt SD, Hofseth LJ, Singh UP, Xie D, Hrushesky WJ. Circadian disruption, Per3, and human cytokine secretion. *Integr Cancer Ther* 2009; **8**: 329-336 [PMID: 19926609 DOI: 10.1177/1534735409352029]

83 **Filipski E**, King VM, Li X, Granda TG, Mormont MC, Claustrat B, Hastings MH, Lévi F. Disruption of circadian coordination accelerates malignant growth in mice. *Pathol Biol (Paris)* 2003; **51**: 216-219 [PMID: 12852994 DOI: 10.1016/S0369-8114(03)00034-8]

84 **Blask DE**, Dauchy RT, Sauer LA, Krause JA, Brainard GC. Growth and fatty acid metabolism of human breast cancer (MCF-7) xenografts in nude rats: impact of constant light-induced nocturnal melatonin suppression. *Breast Cancer Res Treat* 2003; **79**: 313-320 [PMID: 12846415 DOI: [10.1023/A:1024030518065](http://dx.doi.org/10.1023/A:1024030518065)]

85 **Thompson CL**, Larkin EK, Patel S, Berger NA, Redline S, Li L. Short duration of sleep increases risk of colorectal adenoma. *Cancer* 2011; **117**: 841-847 [PMID: 20936662 DOI: 10.1002/cncr.25507]

86 **Reed VA**. Shift work, light at night, and the risk of breast cancer. *AAOHN J* 2011; **59**: 37-45; quiz 46 [PMID: 21175107 DOI: 10.3928/08910162-20101216-01]

87 **Schernhammer ES**, Laden F, Speizer FE, Willett WC, Hunter DJ, Kawachi I, Fuchs CS, Colditz GA. Night-shift work and risk of colorectal cancer in the nurses' health study. *J Natl Cancer Inst* 2003; **95**: 825-828 [PMID: 12783938 DOI: [10.1093/jnci/95.11.825](http://dx.doi.org/10.1093/jnci/95.11.825)]

88 **Wiseman M**. The second World Cancer Research Fund/American Institute for Cancer Research expert report. Food, nutrition, physical activity, and the prevention of cancer: a global perspective. *Proc Nutr Soc* 2008; **67**: 253-256 [PMID: 18452640 DOI: 10.1017/s002966510800712x]

89 **Basterfield L**, Mathers JC. Intestinal tumours, colonic butyrate and sleep in exercised Min mice. *Br J Nutr* 2010; **104**: 355-363 [PMID: 20334709 DOI: 10.1017/s0007114510000528]

90 **Vijayalaxmi CR**, Reiter RJ, Herman TS. Melatonin: from basic research to cancer treatment clinics. *J Clin Oncol* 2002; **20**: 2575-2601 [PMID: 12011138 DOI: [10.1200/JCO.2002.11.004](http://dx.doi.org/10.1200/JCO.2002.11.004)]

91 **Córdoba J,** Cabrera J, Lataif L, Penev P, Zee P, Blei AT. High Prevalence of Sleep Disturbance in Cirrhosis. Hepatology 1998; **27:** 339-45 [PMID: 9462628]

92 **Bismuth M**, Funakoshi N, Cadranel JF, Blanc P. Hepatic encephalopathy: from pathophysiology to therapeutic management. *Eur J Gastroenterol Hepatol* 2011; **23**: 8-22 [PMID: 21099434 DOI: 10.1097/MEG.0b013e3283417567]

93 **Newton JL**, Gibson GJ, Tomlinson M, Wilton K, Jones D. Fatigue in primary biliary cirrhosis is associated with excessive daytime somnolence. *Hepatology* 2006; **44**: 91-98 [PMID: 16800007 DOI: 10.1002/hep.21230]

94 **Martinez OM**, Villanueva JC, Gershwin ME, Krams SM. Cytokine patterns and cytotoxic mediators in primary biliary cirrhosis. *Hepatology* 1995; **21**: 113-119 [PMID: 7806143]

95 **Carlson MD,** Hilsabeck RC, Barakat F, Perry W. Role of Sleep Disturbance in Chronic Hepatitis C Infection. *Curr Hepat Rep* 2010; **9**: 25-29 [PMID: 20208985 DOI: 10.1007/s11901-010-0030-x]

96 **Raison CL**, Rye DB, Woolwine BJ, Vogt GJ, Bautista BM, Spivey JR, Miller AH. Chronic interferon-alpha administration disrupts sleep continuity and depth in patients with hepatitis C: association with fatigue, motor slowing, and increased evening cortisol. *Biol Psychiatry* 2010; **68**: 942-949 [PMID: 20537611 DOI: 10.1016/j.biopsych.2010.04.019]

97 **Summa KC,** Voigt RM, Forsyth CB, Shaikh M, Cavanaugh K, Tang Y, Vitaterna MH, Song S, Turek FW, Keshavarzian A. Disruption of the Circadian Clock in Mice Increases Intestinal Permeability and Promotes Alcohol-Induced Hepatic Pathology and Inflammation. *PLoS One* 2013; **8**: e67102 [PMID: 23825629 DOI: 10.1371/journal.pone.0067102]

98 **Turner JR**. Intestinal mucosal barrier function in health and disease. *Nat Rev Immunol* 2009; **9**: 799-809 [PMID: 19855405 DOI: 10.1038/nri2653]

99 **Rybarczyk B**, Stepanski E, Fogg L, Lopez M, Barry P, Davis A. A placebo-controlled test of cognitive-behavioral therapy for comorbid insomnia in older adults. *J Consult Clin Psychol* 2005; **73**: 1164-1174 [PMID: 16392989 DOI: 10.1037/0022-006X.73.6.1164]

100 **Jungquist CR**, O'Brien C, Matteson-Rusby S, Smith MT, Pigeon WR, Xia Y, Lu N, Perlis ML. The efficacy of cognitive-behavioral therapy for insomnia in patients with chronic pain. *Sleep Med* 2010; **11**: 302-309 [PMID: 20133188 DOI: 10.1016/j.sleep.2009.05.018]

101 **Jungquist CR**, Tra Y, Smith MT, Pigeon WR, Matteson-Rusby S, Xia Y, Perlis ML. The durability of cognitive behavioral therapy for insomnia in patients with chronic pain. *Sleep Disord* 2012; **2012**: 679648 [PMID: 23470897 DOI: 10.1155/2012/679648]

102 **Edinger JD**, Wohlgemuth WK, Krystal AD, Rice JR. Behavioral insomnia therapy for fibromyalgia patients: a randomized clinical trial. *Arch Intern Med* 2005; **165**: 2527-2535 [PMID: 16314551 DOI: 10.1001/archinte.165.21.2527]

103 **Currie SR**, Wilson KG, Pontefract AJ, deLaplante L. Cognitive-behavioral treatment of insomnia secondary to chronic pain. *J Consult Clin Psychol* 2000; **68**: 407-416 [PMID: 10883557]

**P-Reviewer** Chen SJ, Saburi A **S-Editor** Ma YJ L**-Editor** **E-Editor**